These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21981945)

  • 1. Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts.
    Hagtvet E; Røe K; Olsen DR
    Radiat Oncol; 2011 Oct; 6():135. PubMed ID: 21981945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.
    Røe K; Mikalsen LT; van der Kogel AJ; Bussink J; Lyng H; Ree AH; Marignol L; Olsen DR
    Radiat Oncol; 2012 May; 7():75. PubMed ID: 22621752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts.
    Davies Cde L; Lundstrøm LM; Frengen J; Eikenes L; Bruland S ØS; Kaalhus O; Hjelstuen MH; Brekken C
    Cancer Res; 2004 Jan; 64(2):547-53. PubMed ID: 14744768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice.
    Hagtvet E; Evjen TJ; Olsen DR; Fossheim SL; Nilssen EA
    J Drug Target; 2011 Sep; 19(8):701-8. PubMed ID: 21524240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
    Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
    Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
    Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models.
    Burade V; Bhowmick S; Maiti K; Zalawadia R; Ruan H; Thennati R
    BMC Cancer; 2017 Jun; 17(1):405. PubMed ID: 28587612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation.
    Roy Chaudhuri T; Arnold RD; Yang J; Turowski SG; Qu Y; Spernyak JA; Mazurchuk R; Mager DE; Straubinger RM
    Pharm Res; 2012 Dec; 29(12):3312-24. PubMed ID: 22798260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study.
    Røe K; Kakar M; Seierstad T; Ree AH; Olsen DR
    Radiat Oncol; 2011 Jun; 6():65. PubMed ID: 21651782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions.
    Røe K; Seierstad T; Kristian A; Mikalsen LT; Mælandsmo GM; van der Kogel AJ; Ree AH; Olsen DR
    Neoplasia; 2010 Oct; 12(10):818-25. PubMed ID: 20927320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.
    Sapra P; Moase EH; Ma J; Allen TM
    Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DCE-MRI of the hypoxic fraction, radioresponsiveness, and metastatic propensity of cervical carcinoma xenografts.
    Ellingsen C; Hompland T; Galappathi K; Mathiesen B; Rofstad EK
    Radiother Oncol; 2014 Feb; 110(2):335-41. PubMed ID: 24231244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodal approach to assess tumour vasculature and potential treatment effect with DCE-US and DCE-MRI quantification in CWR22 prostate tumour xenografts.
    Arteaga-Marrero N; Rygh CB; Mainou-Gomez JF; Nylund K; Roehrich D; Heggdal J; Matulaniec P; Gilja OH; Reed RK; Svensson L; Lutay N; Olsen DR
    Contrast Media Mol Imaging; 2015; 10(6):428-37. PubMed ID: 26010530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
    Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
    J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma.
    Liu H; Xie Y; Zhang Y; Cai Y; Li B; Mao H; Liu Y; Lu J; Zhang L; Yu R
    Biomaterials; 2017 Mar; 121():130-143. PubMed ID: 28088075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model.
    Franco MS; Roque MC; de Barros ALB; de Oliveira Silva J; Cassali GD; Oliveira MC
    Biomed Pharmacother; 2019 Jan; 109():1728-1739. PubMed ID: 30551427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical studies of pegylated- and non-pegylated liposomal forms of doxorubicin as radiosensitizer on orthotopic high-grade glioma xenografts.
    Chastagner P; Sudour H; Mriouah J; Barberi-Heyob M; Bernier-Chastagner V; Pinel S
    Pharm Res; 2015 Jan; 32(1):158-66. PubMed ID: 25048636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes.
    Sapra P; Allen TM
    Clin Cancer Res; 2004 Apr; 10(7):2530-7. PubMed ID: 15073133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts.
    Ovrebø KM; Ellingsen C; Galappathi K; Rofstad EK
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e121-7. PubMed ID: 22381901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.